Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95

Journal of Neurogenetics

Volumn 28, Issue 1-2, 2014, Pages 98-111

  Zhang, Jingping ^a,b   Saur, Taixiang ^a,c   Duke, Angela N ^a,d   Grant, Seth G N ^e   Platt, Donna M ^a,f   Rowlett, James K ^a,f   Isacson, Ole ^c   Yao, Wei Dong ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MCLEAN HOSPITAL   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Glutamate; Huntington; Striatum

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; COCAINE; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; GLUTAMATE RECEPTOR; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN DARPP 32; POSTSYNAPTIC DENSITY PROTEIN 95; AMINO ACID RECEPTOR AFFECTING AGENT; BENZAZEPINE DERIVATIVE; DLGH4 PROTEIN, MOUSE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; GUANYLATE KINASE; MAGNESIUM; MEMBRANE PROTEIN; PPP1R1B PROTEIN, MOUSE; SK&F 81297;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; EXCITATORY POSTSYNAPTIC POTENTIAL; EXCITOTOXICITY; GENE DELETION; HYPOACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; WILD TYPE; AGE; ANIMAL; CELL COUNT; DEFICIENCY; DEGENERATIVE DISEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; MEMBRANE POTENTIAL; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; AGE FACTORS; ANIMALS; BENZAZEPINES; CELL COUNT; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; EXCITATORY AMINO ACID AGENTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GENE EXPRESSION REGULATION; GLUTAMIC ACID; GUANYLATE KINASE; MAGNESIUM; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84901473809     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2014.892486     Document Type: Article

References (64)

1. Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y. T., Salter, M. W., & Tymianski, M. (2002) Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science, 298, 846-850. (Pubitemid 35231541)
2. Abbas, A. I., Yadav, P. N., Yao, W. D., Arbuckle, M. I., Grant, S. G., Caron, M. G., & Roth, B. L. (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci, 29, 7124-7136.
3. Albin, R. L., Young, A. B., Penney, J. B., Handelin, B., Balfour, R., Anderson, K. D., Markel, D. S., Tourtellotte, W. W., & Reiner, A. (1990). Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington ' s disease. N Engl J Med, 322, 1293-1298. (Pubitemid 20152493)
4. Allbutt, H. N., & Henderson, J. M. (2007). Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson ' s disease. J Neurosci Methods, 159, 195-202. (Pubitemid 44908650)
5. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington ' s disease by quinolinic acid. Nature, 321, 168-171. (Pubitemid 16022019)
6. Beique, J. C., Lin, D. T., Kang, M. G., Aizawa, H., Takamiya K., & Huganir, R. L. (2006). Synapse-specifi c regulation of AMPA receptor function by PSD-95. Proc Natl Acad Sci U S A, 103, 19535-19540. (Pubitemid 46026066)
7. Bozzi, Y., & Borrelli, E. (2006). Dopamine in neurotoxicity and neuroprotection: What do D2 receptors have to do with it Trends Neurosci, 29, 167-174.
8. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., & Bredt, D. S. (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell, 84, 757-767. (Pubitemid 26094205)
9. Camp, M. C., Feyder, M., Ihne, J., Palachick, B., Hurd, B., Karlsson, R. M., Noronha, B., Chen, Y. C., Coba, M. P., Grant, S. G., & Holmes, A. (2011). A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference. Addict Biol, 16, 428-439.
10. Carr, D. B., & Sesack, S. R. (1996). Hippocampal afferents to the rat prefrontal cortex: Synaptic targets and relation to dopamine terminals. J Comp Neurol, 369, 1-15. (Pubitemid 26137477)
11. Cepeda, C., & Levine, M. S. (2006). Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE, 2006, pe20.
12. Cha, J. H. (2007). Transcriptional signatures in Huntington ' s disease. Prog Neurobiol, 83, 228-248.
13. Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1, 623-634.
14. Cyr, M., Beaulieu, J. M., Laakso, A., Sotnikova, T. D., Yao, W. D., Bohn, L. M., Gainetdinov, R. R., & Caron, M. G. (2003). Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A, 100, 11035-11040. (Pubitemid 37140148)
15. Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., & Caron, M. G. (2006). Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J, 20, 2541-2543.
16. Dragatsis, I., Levine, M. S., & Zeitlin, S. (2000). Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet, 26, 300-306.
17. El-Husseini, A. E., Schnell, E., Chetkovich, D. M., Nicoll, R. A., & Bredt, D. S. (2000). PSD-95 involvement in maturation of excitatory synapses. Science, 290, 1364-1368.
18. Elias, G. M., Funke, L., Stein, V., Grant, S. G., Bredt D. S., & Nicoll, R. A. (2006). Synapse-specifi c and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins. Neuron, 52, 307-320. (Pubitemid 44548345)
19. Fan, M. M., & Raymond, L. A. (2007). N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington ' s disease. Prog Neurobiol, 81, 272-293. (Pubitemid 46528641)
20. Fiorentini, C., Rizzetti, M. C., Busi, C., Bontempi, S., Collo, G., Spano, P., & Missale, C. (2006). Loss of synaptic D1 dopamine/N-methyl-D- aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol, 69, 805-812. (Pubitemid 43363855)
21. Freund, T. F., Powell, J. F., & Smith, A. D. (1984). Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identifi ed striatonigral neurons, with particular reference to dendritic spines. Neuroscience, 13, 1189-1215. (Pubitemid 15198966)
22. Futai, K., Kim, M. J., Hashikawa, T., Scheiffele, P., Sheng, M., & Hayashi, Y. (2007). Retrograde modulation of presynaptic release probability through signaling mediated by PSD-95-neuroligin. Nat Neurosci, 10, 186-195. (Pubitemid 46174843)
23. Gardoni, F. (2008). MAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol, 585, 147-152.
24. Gardoni, F., Bellone, C., Viviani, B., Marinovich, M., Meli, E., Pellegrini-Giampietro D. E., Cattabeni, F., & Di Luca M. (2002). Lack of PSD-95 drives hippocampal neuronal cell death through activation of an alpha CaMKII transduction pathway. Eur J Neurosci, 16, 777-786. (Pubitemid 35463569)
25. Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca M., & Calabresi, P. (2006). A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci, 26, 2914-2922.
26. Gerfen, C. R. (1992). The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci, 15, 285-320.
27. Goldman-Rakic P. S., Leranth, C., Williams, S. M., Mons, N., & Geffard, M. (1989). Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci U S A, 86, 9015-9019. (Pubitemid 20010358)
28. Ha, C. M., Park, D., Han, J. K., Jang, J. I., Park, J. Y., Hwang, E. M., Seok, H., & Chang, S. (2012). Calcyon forms a novel ternary complex with dopamine D1 receptor through PSD-95 protein and plays a role in dopamine receptor internalization. J Biol Chem, 287, 31813-31822.
29. Hantraye, P., Riche, D., Maziere, M., & Isacson, O. (1990). A primate model of Huntington ' s disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol, 108, 91-104. (Pubitemid 20153928)
30. Hardingham, G. E., & Bading, H. (2002). Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim Biophys Acta, 1600, 148-153. (Pubitemid 38224409)
31. Hersch, S. M., Ciliax, B. J., Gutekunst, C. A., Rees, H. D., Heilman, C. J., Yung, K. K., Bolam, J. P., Ince, E., Yi, H., & Levey, A. I. (1995). Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci, 15, 5222-5237.
32. Jarabek, B. R., Yasuda, R. P., & Wolfe, B. B. (2004). Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington ' s mouse model. Brain, 127, 505-516. (Pubitemid 38295468)
33. Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Kanki, R., Yamashita, H., & Akaike, A. (2002). Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res, 70, 274-282. (Pubitemid 35222362)
34. Kim, E., & Sheng, M. (2004). PDZ domain proteins of synapses. Nat Rev Neurosci, 5, 771-781. (Pubitemid 39336214)
35. Kruusmagi, M., Kumar, S., Zelenin, S., Brismar, H., Aperia, A., & Scott, L. (2009). Functional differences between D(1) and D(5) revealed by high resolution imaging on live neurons. Neuroscience, 164, 463-469.
36. Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M. F. (2004). Genetic mouse models of Huntington ' s and Parkinson ' s diseases: Illuminating but imperfect. Trends Neurosci, 27, 691-697. (Pubitemid 39335840)
37. Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., Carpenter, E. M., Zanjani, H., Hurst, R. S., Efstratiadis, A., Zeitlin, S., & Chesselet, M. F. (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington ' s disease. J Neurosci Res, 58, 515-532. (Pubitemid 29530435)
38. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., & Bates, G. P. (1996). Exon 1 of the HD gene with an expanded CAG repeat is suffi cient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506. (Pubitemid 26374323)
39. Mantamadiotis, T., Lemberger, T., Bleckmann, S. C., Kern, H., Kretz, O., Martin Villalba A., Tronche, F., Kellendonk, C., Gau, D., Kapfhammer, J., Otto, C., Schmid, W., & Schutz, G. (2002). Disruption of CREB function in brain leads to neurodegeneration. Nat Genet, 31, 47-54.
40. Migaud, M., Charlesworth, P., Dempster, M., Webster, L. C., Watabe, A. M., Makhinson, M., He, Y., Ramsay, M. F., Morris, R. G., Morrison, J. H., O ' Dell T. J., & Grant, S. G. (1998). Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature, 396, 433-439. (Pubitemid 28553306)
41. Milnerwood, A. J., & Raymond, L. A. (2010). Early synaptic pathophysiology in neurodegeneration: Insights from Huntington ' s disease. Trends Neurosci, 33, 513-523.
42. Nash, J. E., Johnston, T. H., Collingridge, G. L., Garner, C. C., & Brotchie, J. M. (2005). Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson ' s disease and L-DOPA-induced dyskinesia. FASEB J, 19, 583-585. (Pubitemid 40471251)
43. Paxinos, G., & Franklin, K. B. J. (2001). The mouse brain in stereotaxic coordinates (4th ed.). San Diego: Academic Press.
44. Porras, G., Berthet, A., Dehay, B., Li, Q., Ladepeche, L., Normand, E., Dovero, S., Martinez, A., Doudnikoff, E., Martin-Negrier M. L., Chuan, Q., Bloch, B., Choquet, D., Boue-Grabot E., Groc, L., & Bezard, E. (2012). PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffi cking. J Clin Invest, 122, 3977-3989.
45. Reddy, P. H., Williams, M., Charles, V., Garrett, L., Pike-Buchanan L., Whetsell, W. O., Jr., Miller, G., & Tagle, D. A. (1998). Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet, 20, 198-202. (Pubitemid 28455456)
46. Riccio, A., & Ginty, D. D. (2002). What a privilege to reside at the synapse: NMDA receptor signaling to CREB. Nat Neurosci, 5, 389-390. (Pubitemid 34454237)
47. Rumbaugh, G., & Vicini, S. (1999). Distinct synaptic and extrasynaptic NMDA receptors in developing cerebellar granule neurons. J Neurosci, 19, 10603-10610. (Pubitemid 30235707)
48. Sattler, R., Xiong, Z., Lu, W. Y., Hafner, M., MacDonald, J. F., & Tymianski, M. (1999). Specifi c coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 284, 1845-1848.
49. Seamans, J. K., Durstewitz, D., Christie, B. R., Stevens, C. F., & Sejnowski, T. J. (2001). Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A, 98, 301-306. (Pubitemid 32095904)
50. Stanley, J. L., Lincoln, R. J., Brown, T. A., McDonald, L. M., Dawson, G. R., & Reynolds, D. S. (2005). The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination defi cits induced by benzodiazepines. J Psychopharmacol, 19, 221-227. (Pubitemid 40694939)
51. Sun, P., Wang, J., Gu, W., Cheng, W., Jin, G. Z., Friedman, E., Zheng, J., & Zhen, X. (2009). PSD-95 regulates D1 dopamine receptor resensitization, but not receptormediated Gs-protein activation. Cell Res, 19, 612-624.
52. Sun, Y., Savanenin, A., Reddy, P. H., & Liu, Y. F. (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem, 276, 24713-24718.
53. The Huntington ' s Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington ' s disease chromosomes. Cell, 72, 971-983.
54. West, M. J. (1993). New stereological methods for counting neurons. Neurobiol Aging, 14, 275-285. (Pubitemid 23214693)
55. West, M. J., & Gundersen, H. J. (1990). Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol, 296, 1-22. (Pubitemid 20174971)
56. Yamada, Y., Chochi, Y., Ko, J. A., Sobue, K., & Inui, M. (1999). Activation of channel activity of the NMDA receptor-PSD-95 complex by guanylate kinase-associated protein (GKAP). FEBS Lett, 458, 295-298. (Pubitemid 29433822)
57. Yamamoto, A., Lucas, J. J., & Hen, R. (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington ' s disease. Cell, 101, 57-66.
58. Yao, W. D., Gainetdinov, R. R., Arbuckle, M. I., Sotnikova, T. D., Cyr, M., Beaulieu, J. M., Torres, G. E., Grant, S. G., & Caron, M. G. (2004). Identifi cation of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron, 41, 625-638. (Pubitemid 38253073)
59. Yao, W. D., Spealman, R. D., & Zhang, J. (2008). Dopaminergic signaling in dendritic spines. Biochem Pharmacol, 75, 2055-2069.
60. Young, A. B., Greenamyre, J. T., Hollingsworth, Z., Albin, R., D ' Amato C., Shoulson, I., & Penney, J. B. (1988). NMDA receptor losses in putamen from patients with Huntington ' s disease. Science, 241, 981-983.
61. Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington ' s disease. Neuron, 33, 849-860. (Pubitemid 34246352)
62. Zhang, J., Vinuela, A., Neely, M. H., Hallett, P. J., Grant, S. G., Miller, G. M., Isacson, O., Caron, M. G., & Yao, W. D. (2007). Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem, 282, 15778-15789. (Pubitemid 47093305)
63. Zhang, J., Xu, T. X., Hallett, P. J., Watanabe, M., Grant, S. G., Isacson, O., & Yao, W. D. (2009). PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci, 29, 2948-2960.
64. Zucker, B., Luthi-Carter R., Kama, J. A., Dunah, A. W., Stern, E. A., Fox, J. H., Standaert, D. G., Young, A. B., & Augood, S. J. (2005). Transcriptional dysregulation in striatal projection and interneurons in a mouse model of Huntington ' s disease: Neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet, 14, 179-189.